Cardiovascular device company Sorin Group has invested $20 million in Respicardia. The financing is to be used to fund ongoing clinical testing of the startup's remede System, which is a pacemaker-like device for central sleep apnea that delivers electrical pulses via an implantable lead to the phrenic nerve.
Privacy concerns and cost are two of the leading barriers to adoption of wearable medical devices, PwC said in two reports released today on the future of wearable technology.
Genomic sequencing seems to have come of age with Illumina as a substantial driver and beneficiary. During the third quarter, the company achieved astonishing revenue growth of 35% to $481 million over the same quarter last year.
As med tech companies set their sights on wearable technology with 3-D imaging capabilities, a Florida startup brought in $542 million in VC funding to develop its innovative eyeglasses-like device that could provide a new interface for patient-doctor communication.
Reaction time can be a sign of brain injuries that are common on the battlefield such as concussion, dementia, post-traumatic stress and depression, says product developer AnthroTronix.
Researchers hope that a new implantable device that encapsulates and nurtures pancreatic beta cells will provide sufficient insulin to Type 1 diabetes patients. The first patient in an 8-patient clinical trial has already been implanted with the device, the βAir Bio-Artificial Pancreas from Israeli startup Beta-O2.
Medrobotics, a surgical products company focused on medical robotics, raised $20 million in equity financing.
FierceMedicalDevices caught up with Covidien Chief Medical Officer Dr. Michael Tarnoff at the annual AdvaMed conference in Chicago at the beginning of October. Tarnoff also performs minimally invasive and bariatric surgery part-time at Tufts Medical Center in Boston.
St. Louis, MO-based Veran Medical closed a $12 million financing round. The company, specializing in thoracic navigation an biopsy for early detection of lung cancer, will use the funds toward continued commercial expansion in the U.S. and international launch of the Veran Thoracic Navigation System.
Punctum plugs improve patient compliance and deliver drugs to the eye effectively, said the American Academy of Ophthalmology, citing the results of a Phase II study of Ocular Therapeutix's dexamethasone delivering plug, whose length is a fraction of the diameter of a dime.
Philips shed as much as 4% in early trading as continued manufacturing problems and intellectual property litigation as well as weakness in Russia and China weighed on investor confidence after it reported third-quarter results.
Dexcom won FDA approval for its next-generation mobile communications device for diabetes monitoring, chalking up another regulatory win and furthering the company's R&D push.
Strands of DNA interlocked like Lego bricks could become the key ingredient for tomorrow's nanoscale devices, Harvard University's Wyss Institute for Biologically Inspired Engineering says.
Abbott made separate announcements related to devices focused on the eyes. The first was for a deal it reached with Carl Zeiss Meditec to sell the Swiss lensmaker's cataract surgery products alongside its own ocular surgery devices.
Preimplantation genetic screening and diagnostics provider Reprogenetics is partnering with Illumina to use its next-generation sequencing tech in its analysis of embryos and infertility.
Minnesota's Mayo Clinic is suing one of its former top executives for misappropriation of trade secrets as part of a plan to work for competitor Quest Diagnostics following a false retirement.
John Dineen has already found a posh new gig only a few weeks after his departure from GE Healthcare as its newpresident and CEO was announced. He will join private equity firm Clayton, Dubilier & Rice (CD&R) early next year as an operating adviser to its funds.
Stryker took an earnings hit during the third quarter, in part to repatriate $2 billion in cash for acquisitions and to establish an EU regional headquarters in Amsterdam, where it has moved some intellectual property. The IP transfer is expected to reduce its effective tax rate from an expected 22% in 2014 to 20% next year.
Boston Scientific won CE-mark approval for a new suite of MRI-friendly pacemaker products, boosting its product offerings and furthering its plan of revitalizing sales for its sluggish cardiac unit.